Ask Lonic

What would you like to know?

Answers are drawn from Lonic's published reporting on lonic.bond, with every source listed.

No account needed — answers are generated from our article library.

Answer

GLP-1

Weight loss drugs generate tens of thousands of searches a month and an unusual volume of certainty in both directions. The evidence base has grown enough to say something more precise: GLP-1 receptor agonists produce clinically meaningful weight reduction for most people who take them, deliver cardiovascular and metabolic benefits beyond weight itself, and come with real trade-offs around cost, muscle loss and discontinuation.

  • Average weight reduction in the mid-teens as a percentage of body weight, with wide individual variation.
  • Reduced major cardiovascular events in patients with existing risk, independent of how much weight was lost.
  • Improvements in sleep apnoea, joint pain and markers of liver disease in several sub-populations.
  • High discontinuation rates in real-world use — cost and gastrointestinal side effects dominate.

Read more about this

People also asked

Browse the whole library

New here? Start with today's trending stories or read how Lonic reports.